GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027

Lifesciences | Pharmaceuticals

GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027

Market By Dosages, Formulation And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

A detailed analysis by Triton has found that the global hyperphosphatemia drugs market is expected to display a positive market trend over the forecast period of 2019-2027, exhibiting a CAGR of 16.61%. The market was assessed to be worth $2873.67 million in the year 2018 and is predicted to generate a revenue of approximately $11480.07 million by the year 2027.

Report scope can be customized per your requirements. Request For Customization

Hyperphosphatemia is a condition of electrolyte disturbance in the body, with an abnormal increase in the blood’s phosphate levels. Generally, calcium levels are reduced (hypocalcemia) because the phosphate precipitates with the calcium in the tissues. The average levels of phosphorus should ideally range from 0.81 mmol per liter to 1.45 mmol per liter. 

Hyperphosphatemia is diagnosed by the process of measuring the phosphate concentration in the blood. A phosphate concentration >1.46 mmol/L (4.5 mg/dL) indicates the presence of hyperphosphatemia. However, further tests may be necessary to identify the root cause of the elevated phosphate levels. The formulation of hyperphosphatemia drugs is applied extensively for different purposes. Calcium-based phosphate binders took the place of aluminum-based phosphate binders and have been used since the 1990s. Calcium-based phosphate binders are also used as calcium supplements. Aluminum-based phosphate binders have been used for a long time for treating hyperphosphatemia in dialysis patients. Also, the magnesium-based phosphorus binders are prominently used in the treatment of hyperphosphatemia conditions in all dialysis patients. Iron-based phosphate binders such as sevelamer are impactful in curing hyperphosphatemia and anemia. These binders are associated with an iron surplus in the body. 

The global hyperphosphatemia drugs market report covers the present market situation and the growth prospects of the global hyperphosphatemia drugs market for the period of 2019-2027 and considers the revenue generated due to the sales of hyperphosphatemia drugs for the types as well as the applications to calculate the market size by considering 2017 as the base year.

Within this report from Triton on the global hyperphosphatemia drugs market, Porter’s five force model, key buying outlook, key insights, key market trends and guidance related to phosphate binders have been studied. 

Market drivers like the growing prevalence of chronic diseases, increase in public cognizance and increase in the geriatric population have been analyzed. The industry is facing restraints like limitations levied by the Food and Drug Administration (FDA) and the growing side-effects of hyperphosphatemia drugs, which are obstructing the industry growth.

Key opportunities like the rising aging population can be leveraged by the industry to get towards the projected growth. However, non-adherence to treatment regiments, limited availability of drugs and the use of advanced dialysis techniques are the challenges facing the market at this moment.

To get detailed insights on segments, Download Sample Report

Geographies covered for the global hyperphosphatemia drugs market:

•    North America: the United States and Canada

•    Europe: the United Kingdom, Germany, France, Italy, Spain and Rest of Europe

•    Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia and Rest of Asia-Pacific

•    Latin America: Brazil, Mexico and Rest of Latin America

•    The Middle East and Africa: the United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of Middle East & Africa

The global hyperphosphatemia drugs market is segmented into:

•    By dosages:

O    Solid

•    Tablet

•    Powder

O    Liquid

•    Solution

•    By formulation:

O    Calcium-based phosphate binders

O    Aluminum-based phosphate binders

O    Magnesium-based phosphate binders

O    Iron-based phosphate binders

O    Other phosphate binders

The top key players in the hyperphosphatemia drugs market are Royal DSM N.V., Sanofi, Bio-Tech Pharmacal, Fresenius Medical Care, Keryx Biopharmaceuticals, Inc., Roche Diagnostics Corporation, Shire, Fermenta Biotech, Ltd., Sun Pharmaceutical Industries, Ltd., Cipla, Pfizer, Inc., AMAG Pharmaceuticals, Johnson and Johnson, Bruno Farmaceutici S.p.A., Ultragenyx Pharmaceutical, Inc. and Zeria Pharmaceutical.

The strategic analysis for each of these companies has been covered in detail in the report. The company market share helps to dive into the information about the key market players in the industry and their corresponding hold in the market.


Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCE MODEL

2.2.1.   THREAT OF NEW ENTRANTS

2.2.2.   BARGAINING POWER OF BUYERS

2.2.3.   BARGAINING POWER OF SUPPLIERS

2.2.4.   THREAT OF SUBSTITUTE PRODUCT

2.2.5.   INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. KEY BUYING OUTLOOK

2.5. KEY INSIGHTS

2.6. KEY MARKET TRENDS

2.7. GUIDELINES RELATED TO THE PHOSPHATE BINDERS

2.8. MARKET DRIVERS

2.8.1.   CHRONIC DISORDERS ARE INCREASING RAPIDLY

2.8.2.   INCREASE IN PUBLIC COGNIZANCE

2.8.3.   INCREASE IN GERIATRIC POPULATION

2.9. MARKET RESTRAINTS

2.9.1.   SIDE-EFFECTS RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS

2.9.2.   STRICT FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS

2.10.            MARKET OPPORTUNITIES

2.10.1.                RISE IN THE AGING POPULATION

2.11.            MARKET CHALLENGES

2.11.1.                ALTERNATIVE DIALYSIS TECHNIQUES

2.11.2.                ACCESSIBILITY OF DRUGS IS LIMITED

2.11.3.                NON-ADHERENCE TO TREATMENT REGIMES

3.    HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK - BY DOSAGES

3.1. SOLID

3.1.1.   TABLET

3.1.2.   POWDER

3.2. LIQUID

3.2.1.   SOLUTION

4.    HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK - BY FORMULATION

4.1.1.   CALCIUM-BASED PHOSPHATE BINDERS

4.1.2.   ALUMINUM-BASED PHOSPHATE BINDERS

4.1.3.   MAGNESIUM-BASED PHOSPHATE BINDERS

4.1.4.   IRON-BASED PHOSPHATE BINDERS

4.1.5.   OTHER PHOSPHATE BINDERS

5.    HYPERPHOSPHATEMIA DRUGS INDUSTRY – REGIONAL OUTLOOK

5.1. NORTH AMERICA

5.1.1.   MARKET BY FORMULATION

5.1.2.   COUNTRY ANALYSIS

5.1.2.1.      UNITED STATES

5.1.2.2.      CANADA

5.2. EUROPE

5.2.1.   MARKET BY FORMULATION

5.2.2.   COUNTRY ANALYSIS

5.2.2.1.      UNITED KINGDOM

5.2.2.2.      FRANCE

5.2.2.3.      GERMANY

5.2.2.4.      SPAIN

5.2.2.5.      ITALY

5.2.2.6.      RUSSIA

5.2.2.7.      REST OF EUROPE (ROE)

5.3. ASIA PACIFIC

5.3.1.   MARKET BY FORMULATION

5.3.2.   COUNTRY ANALYSIS

5.3.2.1.      INDIA

5.3.2.2.      CHINA

5.3.2.3.      JAPAN

5.3.2.4.      AUSTRALIA

5.3.2.5.      REST OF APAC

5.4. LATIN AMERICA

5.4.1.   MARKET BY FORMULATION

5.4.2.   COUNTRY ANALYSIS

5.4.2.1.      BRAZIL

5.4.2.2.      MEXICO

5.4.2.3.      REST OF LATIN AMERICA

5.5. MIDDLE EAST AND AFRICA (MEA)

5.5.1.   MARKET BY FORMULATION

5.5.2.   COUNTRY ANALYSIS

5.5.2.1.      SAUDI ARABIA

5.5.2.2.      TURKEY

5.5.2.3.      UNITED ARAB EMIRATES

5.5.2.4.      SOUTH AFRICA

5.5.2.5.      REST OF MIDDLE EAST AND AFRICA

6.    COMPETITIVE LANDSCAPE

6.1. JOHNSON AND JOHNSON

6.2. ZERIA PHARMACEUTICAL

6.3. AMAG PHARMACEUTICALS

6.4. SANOFI

6.5. BRUNO FARMACEUTICI S.P.A.

6.6. ROCHE DIAGNOSTICS CORPORATION

6.7. ROYAL DSM N.V.

6.8. SHIRE

6.9. CIPLA

6.10.            ULTRAGENYX PHARMACEUTICAL, INC.

6.11.            FERMENTA BIOTECH, LTD.

6.12.            BIOTECH PHARMACAL

6.13.            SUN PHARMACEUTICAL INDUSTRIES, LTD.

6.14.            KERYX BIOPHARMACEUTICALS, INC.

6.15.            FRESENIUS MEDICAL CARE

6.16.            PFIZER, INC.

7.    METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

List of table

TABLE 1        GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 2        PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3        GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)

TABLE 4        DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5        NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)

TABLE 6        NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)

TABLE 7        EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)

TABLE 8        EUROPE HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)

TABLE 9        ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)

TABLE 10      ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)

TABLE 11      PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA

TABLE 12      LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)

TABLE 13      LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)

TABLE 14      MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)

TABLE 15      MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)

List of Figures

FIGURE 1      PORTER’S FIVE FORCE MODEL OF HYPERPHOSPHATEMIA MARKET

FIGURE 2      IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3      GLOBAL POPULATION AGED 80 AND ABOVE 1950-2050 (MILLION)

FIGURE 4      RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 5      GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 6      GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 7      GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 8      GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 9      GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 10   GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET SHARE BY REGION 2018 & 2027 (%)

FIGURE 11   NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 12   UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 13   CANADA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 14   EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 15   UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 16   FRANCE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 17   GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 18   SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 19   ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 20   RUSSIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 21   REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 22   ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 23   AGEWISE DISTRIBUTION OF ELDERLY POPULATION IN INDIA

FIGURE 24   INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 25   CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 26   JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 27   NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA

FIGURE 28   SOUTH KOREA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 29   ASEAN COUNTRIESHYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 30   AUSTRALIA & NEW ZEALAND HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 31   ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 32   LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 33   BRAZIL HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 34   MEXICO HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 35   REST OF LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 36   MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 37   SAUDI ARABIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 38   TURKEY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 39   UNITED ARAB EMIRATES HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 40   SOUTH AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 41   REST OF MIDDLE EAST & AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;